Clinical and Experimental Nephrology

, Volume 14, Issue 5, pp 457–462 | Cite as

Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome

  • Akio Nakamura
  • Ryo Niimi
  • Kumiko Kurosaki
  • Yukishige Yanagawa
Original Article



This study attempted to identify the cardiovascular risk factors associated with retention of excess weight following termination of glucocorticoid therapy in children with nephrotic syndrome.


We performed a retrospective study of 30 Japanese children (18 males, 12 females, aged 1–14 years) who had been treated with glucocorticoids for steroid-sensitive nephrotic syndrome and 32 control children (17 males, 15 females, aged 1–15 years). The subjects receiving glucocorticoid therapy were divided into a retention group (n = 14) or a reduction group (n = 16) on the basis of the presence or absence of a maintained body mass index (BMI) following glucocorticoid termination. BMI z-scores, age, gender, blood pressure, serum total cholesterol levels (T-cho), and the dose and duration of glucocorticoid exposure were evaluated in each group during the study period.


The retention group had a significantly (P < 0.05) increased dose and duration of glucocorticoid exposure, and of T-cho at the time of last visit compared with the control or reduction group. Moreover, logistic regression analysis showed that the adjusted odds ratio for T-cho at the time of last visit in the retention group was significantly higher (P < 0.05) relative to the reduction group.


Retention of excess weight during the period of remission from nephrotic syndrome following cessation of glucocorticoid therapy was related to the dose and duration of glucocorticoid exposure and was associated with hyperlipidemia, which might enhance cardiovascular risk.


Clinical nephrology Cortisol Lipids Nephrotic syndrome Obesity 



We are very grateful for support from the Mitsui Life Social Welfare Foundation and Mitsukoshi Welfare Foundation. We thank Dr. Kouhei Uemura in the Department of Epidemiology and Biostatistics in University of Tokyo, Tokyo, Japan, for assistance with statistical analysis. We also thank Prof. E. J. Johns, Department of Physiology, University of Cork, Ireland, for critical review of the manuscript and suggestions.


  1. 1.
    Merritt RJ, Hack SL, Kalsch M, Olson D. Corticosteroid therapy-induced obesity in children. Clin Pediatr (Phila). 1986;25:149–52.CrossRefGoogle Scholar
  2. 2.
    Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–602.CrossRefPubMedGoogle Scholar
  3. 3.
    Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H. Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1993;7:249–52.CrossRefPubMedGoogle Scholar
  4. 4.
    Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr. 1988;27:387–92.CrossRefGoogle Scholar
  5. 5.
    Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J. Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr. 1984;104:61–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Kniazewska MH, Obuchowicz AK, Wielkoszyński T, Zmudzińska-Kitczak J, Urban K, Marek M, et al. Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome. Pediatr Nephrol. 2009;24:549–54.CrossRefPubMedGoogle Scholar
  7. 7.
    International Study of Kidney Disease in Children. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. J Pediatr. 1979; 95:239–43.Google Scholar
  8. 8.
    Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985;106:522–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Inokuchi M, Matsuo N, Anzo M, Hasegawa T. Body mass index reference values (mean and SD) for Japanese children. Acta Paediatr. 2007;96:1674–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Troiano RP and Flegal KM. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics. 1998;101:497–504.Google Scholar
  11. 11.
    Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005;147:202–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124:747–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Foster BJ, Shults J, Zemel BS, Leonard MB. Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2006;21:973–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Wisniewski AB, Chernausek SD. Gender in childhood obesity: family environment, hormones, and genes. Gend Med. 2009;6(Suppl 1):76–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol. 2003;85:457–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J. 1999;92:898–904.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2010

Authors and Affiliations

  • Akio Nakamura
    • 1
  • Ryo Niimi
    • 1
  • Kumiko Kurosaki
    • 1
  • Yukishige Yanagawa
    • 1
  1. 1.Department of PaediatricsTeikyo University School of MedicineTokyoJapan

Personalised recommendations